User login
CLINICAL UPDATE
A supplement to Family Practice News. Funding for this publication was provided by Cephalon, Inc.
•Topic Highlights
•Faculty/Faculty Disclosure
• Cyclobenzaprine Extended-Release (CER) Capsules
• CER for Acute Muscle Spasm: Evaluating the Evidence
• What is the background on the AMRIX clinical study program?
• What were the methodology and patient population for the studies?
• What were the key outcome measures?
• What were the major efficacy findings?
• What was the observed tolerability profile of CER?
• What are the strengths and limitations of these studies?
• What are the important clinical implications of these studies?
Faculty/Faculty Disclosure
Gary E. Ruoff, MD
Clinical Professor of Family Medicine
Michigan State University College of Human Medicine
East Lansing, MI
Dr. Ruoff is on the advisory boards of and has participated in a lecture series for Cephalon, Inc., GlaxoSmithKline, and Takeda Pharmaceuticals North America, Inc. He has conducted research for Abbott Laboratories, Cephalon, Inc., GlaxoSmithKline, Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.
Copyright © 2009 Elsevier Inc.
A supplement to Family Practice News. Funding for this publication was provided by Cephalon, Inc.
•Topic Highlights
•Faculty/Faculty Disclosure
• Cyclobenzaprine Extended-Release (CER) Capsules
• CER for Acute Muscle Spasm: Evaluating the Evidence
• What is the background on the AMRIX clinical study program?
• What were the methodology and patient population for the studies?
• What were the key outcome measures?
• What were the major efficacy findings?
• What was the observed tolerability profile of CER?
• What are the strengths and limitations of these studies?
• What are the important clinical implications of these studies?
Faculty/Faculty Disclosure
Gary E. Ruoff, MD
Clinical Professor of Family Medicine
Michigan State University College of Human Medicine
East Lansing, MI
Dr. Ruoff is on the advisory boards of and has participated in a lecture series for Cephalon, Inc., GlaxoSmithKline, and Takeda Pharmaceuticals North America, Inc. He has conducted research for Abbott Laboratories, Cephalon, Inc., GlaxoSmithKline, Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.
Copyright © 2009 Elsevier Inc.
A supplement to Family Practice News. Funding for this publication was provided by Cephalon, Inc.
•Topic Highlights
•Faculty/Faculty Disclosure
• Cyclobenzaprine Extended-Release (CER) Capsules
• CER for Acute Muscle Spasm: Evaluating the Evidence
• What is the background on the AMRIX clinical study program?
• What were the methodology and patient population for the studies?
• What were the key outcome measures?
• What were the major efficacy findings?
• What was the observed tolerability profile of CER?
• What are the strengths and limitations of these studies?
• What are the important clinical implications of these studies?
Faculty/Faculty Disclosure
Gary E. Ruoff, MD
Clinical Professor of Family Medicine
Michigan State University College of Human Medicine
East Lansing, MI
Dr. Ruoff is on the advisory boards of and has participated in a lecture series for Cephalon, Inc., GlaxoSmithKline, and Takeda Pharmaceuticals North America, Inc. He has conducted research for Abbott Laboratories, Cephalon, Inc., GlaxoSmithKline, Merck & Co., Inc., and Takeda Pharmaceuticals North America, Inc.
Copyright © 2009 Elsevier Inc.
CLINICAL UPDATE
CLINICAL UPDATE
